Literature DB >> 34353284

Dynamic profile of SARS-CoV-2 infection among hospitalized patients in Kuwait: a descriptive study.

Nada Madi1, Ebaa' Al-Awadhi2, Fajer Al-Assaf3.   

Abstract

BACKGROUND: The coronavirus induced disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan (China) in December 2019 is currently spreading rapidly worldwide. This study aimed to analyze the dynamic profile of SARS-CoV-2 infection among hospitalized patients that would characterize the period of viral shedding and detection among patients.
METHODS: Retrospectively, 103 confirmed SARS-CoV-2 patients hospitalized at Jaber hospital in Kuwait were included. Demographic and clinical characteristics of the patients were collected. Nasopharyngeal swabs were obtained at different time intervals and analyzed by Real-Time RT-PCR for SARS-CoV-2 infection.
RESULTS: Of 103 hospitalized patients with SARS-CoV-2 infection, the median age was 41 years, and 64% were male. The median period from admission to the positive SARS-CoV-2 RT-PCR test was 19 days (IQR, 13-22). The median period from admission to active negative SARS-CoV-2 RT-PCR test result was 22 days (IQR, 16-26). Older patients, patients with comorbidities, and patients with symptoms were more likely to have extended viral shedding.
CONCLUSION: For the first time, this descriptive study conducted in Kuwait on SARS-CoV-2 RT-PCR test results from 103 patients positive for SARS-provided solid proof and a good understanding of the dynamic profile of SARS-CoV-2 infection among patients in Kuwait. This information will further enrich the global knowledge on the emerging SARS-CoV-2.
© 2021. The Author(s).

Entities:  

Keywords:  COVID-19; Kuwait; RT-PCR; SARS-CoV-2

Year:  2021        PMID: 34353284     DOI: 10.1186/s12879-021-06504-x

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  15 in total

1.  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Authors:  Michel Attal; Paul G Richardson; S Vincent Rajkumar; Jesus San-Miguel; Meral Beksac; Ivan Spicka; Xavier Leleu; Fredrik Schjesvold; Philippe Moreau; Meletios A Dimopoulos; Jeffrey Shang-Yi Huang; Jiri Minarik; Michele Cavo; H Miles Prince; Sandrine Macé; Kathryn P Corzo; Frank Campana; Solenn Le-Guennec; Franck Dubin; Kenneth C Anderson
Journal:  Lancet       Date:  2019-11-14       Impact factor: 79.321

2.  Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.

Authors:  Na Zhang; Jing-Bo Shao; Hong Li; Jing-Wei Yang; Kai Chen; Jia-Shi Zhu; Hui Jiang
Journal:  World J Pediatr       Date:  2019-11-20       Impact factor: 2.764

3.  Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Authors:  Maria-Victoria Mateos; Michele Cavo; Joan Blade; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Maria Krevvata; Ying Chen; Jianping Wang; Anupa Kudva; Jon Ukropec; Susan Wroblewski; Ming Qi; Rachel Kobos; Jesus San-Miguel
Journal:  Lancet       Date:  2019-12-10       Impact factor: 79.321

4.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Authors:  Roy S Herbst; Giuseppe Giaccone; Filippo de Marinis; Niels Reinmuth; Alain Vergnenegre; Carlos H Barrios; Masahiro Morise; Enriqueta Felip; Zoran Andric; Sarayut Geater; Mustafa Özgüroğlu; Wei Zou; Alan Sandler; Ida Enquist; Kimberly Komatsubara; Yu Deng; Hiroshi Kuriki; Xiaohui Wen; Mark McCleland; Simonetta Mocci; Jacek Jassem; David R Spigel
Journal:  N Engl J Med       Date:  2020-10-01       Impact factor: 91.245

5.  Facial Masking for Covid-19. Reply.

Authors:  Monica Gandhi; George W Rutherford
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

Review 6.  Active case finding with case management: the key to tackling the COVID-19 pandemic.

Authors:  Zhongjie Li; Qiulan Chen; Luzhao Feng; Lance Rodewald; Yinyin Xia; Hailiang Yu; Ruochen Zhang; Zhijie An; Wenwu Yin; Wei Chen; Ying Qin; Zhibin Peng; Ting Zhang; Daxin Ni; Jinzhao Cui; Qing Wang; Xiaokun Yang; Muli Zhang; Xiang Ren; Dan Wu; Xiaojin Sun; Yuanqiu Li; Lei Zhou; Xiaopeng Qi; Tie Song; George F Gao; Zijian Feng
Journal:  Lancet       Date:  2020-06-04       Impact factor: 79.321

7.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.

Authors:  Camilla Rothe; Mirjam Schunk; Peter Sothmann; Gisela Bretzel; Guenter Froeschl; Claudia Wallrauch; Thorbjörn Zimmer; Verena Thiel; Christian Janke; Wolfgang Guggemos; Michael Seilmaier; Christian Drosten; Patrick Vollmar; Katrin Zwirglmaier; Sabine Zange; Roman Wölfel; Michael Hoelscher
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

8.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.

Authors:  Melissa M Arons; Kelly M Hatfield; Sujan C Reddy; Anne Kimball; Allison James; Jesica R Jacobs; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Jonathan W Dyal; Josh Harney; Zeshan Chisty; Jeneita M Bell; Mark Methner; Prabasaj Paul; Christina M Carlson; Heather P McLaughlin; Natalie Thornburg; Suxiang Tong; Azaibi Tamin; Ying Tao; Anna Uehara; Jennifer Harcourt; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Patty Montgomery; Nimalie D Stone; Thomas A Clark; Margaret A Honein; Jeffrey S Duchin; John A Jernigan
Journal:  N Engl J Med       Date:  2020-04-24       Impact factor: 91.245

9.  A highly effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 infection.

Authors:  Veronica L Fowler; Bryony Armson; Jose L Gonzales; Emma L Wise; Emma L A Howson; Zoe Vincent-Mistiaen; Sarah Fouch; Connor J Maltby; Seden Grippon; Simon Munro; Lisa Jones; Tom Holmes; Claire Tillyer; Joanne Elwell; Amy Sowood; Oliver de Peyer; Sophie Dixon; Thomas Hatcher; Helen Patrick; Shailen Laxman; Charlotte Walsh; Michael Andreou; Nick Morant; Duncan Clark; Nathan Moore; Rebecca Houghton; Nicholas J Cortes; Stephen P Kidd
Journal:  J Infect       Date:  2020-11-30       Impact factor: 6.072

Review 10.  SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.

Authors:  Firas A Rabi; Mazhar S Al Zoubi; Ghena A Kasasbeh; Dunia M Salameh; Amjad D Al-Nasser
Journal:  Pathogens       Date:  2020-03-20
View more
  1 in total

1.  Molecular epidemiology and genetic characterization of SARS-CoV-2 in Kuwait: A descriptive study.

Authors:  Nada Madi; Hussain A Safar; Abu Salim Mustafa; Wassim Chehadeh; Mohammad Asadzadeh; Mohammed Sadeq; Ebaa Alawadhi; Ali Al-Muhaini; Fahad A Benthani
Journal:  Front Microbiol       Date:  2022-08-26       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.